Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fragmin
Drug ID BADD_D00974
Description Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Indications and Usage It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.
Marketing Status Prescription; Discontinued
ATC Code B01AB04
DrugBank ID DB06779
KEGG ID D03353
MeSH ID D017985
PubChem ID Not Available
TTD Drug ID D08PSU
NDC Product Code Not Available
Synonyms Dalteparin | Tedelparin | FR-860 | FR 860 | FR860 | Kabi-2165 | Kabi 2165 | Kabi2165 | Dalteparin Sodium | Sodium, Dalteparin | Fragmin | Fragmine
Chemical Information
Molecular Formula Not Available
CAS Registry Number 9005-49-6
SMILES Not Available
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemarthrosis24.07.01.046; 15.01.01.004; 12.04.03.001--Not Available
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematoma24.07.01.001--
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.006--Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Headache17.14.01.001--
Henoch-Schonlein purpura24.07.06.003; 23.06.01.002; 10.02.02.004; 01.01.04.001--Not Available
Hepatitis cholestatic09.01.01.002--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hyperkalaemia14.05.03.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoaldosteronism14.11.01.031; 05.01.02.009--Not Available
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Hypotonia neonatal18.04.01.006; 17.05.02.010; 15.05.04.012--Not Available
Immune system disorder10.02.01.001--Not Available
Impaired healing08.03.02.001--Not Available
Increased tendency to bruise24.07.06.012; 23.06.01.009; 01.01.03.005--Not Available
Infection11.01.08.002--Not Available
Injection site haematoma24.07.01.009; 12.07.03.004; 08.02.03.004--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia17.15.03.002; 19.02.01.002--
Instillation site pain12.07.01.008; 08.02.01.008--Not Available
Lacrimation increased06.08.02.004--
Local reaction08.01.03.012--Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages